Repositório Científico do Instituto Nacional de Saúde >
Departamento de Genética Humana >
DGH - Artigos em revistas internacionais >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10400.18/168

Title: A multilocus technique for risk evaluation of patients with neuroblastoma
Authors: Ambros, Inge M.
Brunner, Bettina
Aigner, Gerhard
Bedwell, Clare
Beiske, Klaus
Bénard, Jean
Bown, Nick
Combaret, Valerie
Couturier, Jerome
Defferrari, Raffaella
Gross, Nicole
Jeison, Marta
Lunec, John
Marques, Barbara
Martinsson, Tommy
Mazzocco, Katia
Noguera, Rosa
Schleiermacher, Gudrun
Speleman, Frank
Stallings, Ray
Tonini, Gian Paolo
Tweddle, Deborah A.
Valent, Alexander
Vicha, Ales
Van Roy, Nadine
Villamon, Eva
Ziegler, Andrea
Preuner, Sandra
Drobics, Mario
Ladenstein, Ruth
Amann, Gabriele
Schuit, Robert J.L.
Pötschger, Ulrike
Ambros, Peter F.
Keywords: Doenças Genéticas
Issue Date: 15-Feb-2011
Publisher: American Association for Cancer Research Journals
Citation: Clin Cancer Res. 2011 Feb 15;17(4):792-804
Abstract: Purpose: Precise and comprehensive analysis of neuroblastoma genetics is essential for accurate risk evaluation and only pangenomic/multilocus approaches fulfill the present-day requirements. We present the establishment and validation of the PCR-based multiplex ligation-dependent probe amplification (MLPA) technique for neuroblastoma. Experimental Design: A neuroblastoma-specific MLPA kit was designed by the SIOP Europe Neuroblastoma Biology Committee in cooperation with MRC-Holland. The contained target sequences cover 19 chromosomal arms and reference loci. Validation was performed by single locus and pangenomic techniques (n ¼ 174). Dilution experiments for determination of minimal tumor cell percentage were performed and testing of reproducibility was checked by interlaboratory testing (n ¼ 15). Further 156 neuroblastomas were used for establishing the amplification cutoff level. Results: The MLPA technique was tested in 310 neuroblastomas and 8 neuroblastoma cell lines (including validation and amplification cutoff level testing). Intertechnique validation showed a high concordance rate (99.5%). Interlaboratory MLPA testing (k ¼ 0.95, P < 0.01) revealed 7 discrepant of 1,490 results (0.5%). Validation by pangenomic techniques showed a single discordance of 190 consensus results (0.5%). The test results led to formulation of interpretation standards and to a kit revision. The minimal tumor cell percentage was fixed at 60%. Conclusions: The recently designed neuroblastoma-specific MLPA kit covers all chromosomal regions demanded by the International Neuroblastoma Risk Group for therapy stratification and includes all hitherto described genetic loci of prognostic interest for future studies and can be modified or extended at any time. Moreover, the technique is cost effective, reliable, and robust with a high interlaboratory and intertechnique concordance.
Peer Reviewed: yes
URI: http://hdl.handle.net/10400.18/168
ISSN: 1557-3265
Publisher version: http://clincancerres.aacrjournals.org/content/17/4/792.abstract
Appears in Collections:DGH - Artigos em revistas internacionais

Files in This Item:

File Description SizeFormat
Clin Cancer Res; 17(4); 792–804_2011.pdf985.64 kBAdobe PDFView/Open
Restrict Access. You can request a copy!
Statistics
FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpaceOrkut
Formato BibTex mendeley Endnote Logotipo do DeGóis 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

  © 2010 www.insa.pt - Todos os direitos reservados | Feedback Ministério da Saúde

Estamos no RCAAP Governo Português separator Ministério da Educação e Ciência   Fundação para a Ciência e a Tecnologia

Financiado por:

POS_C UE